CEGEDIM produktové protfólio Hotel Kaskády

Similar documents
Cegedim Commercial success under tough conditions. November, 9 th 2011

Bribery and Corruption

This presentation contains forward-looking statements (made pursuant to the safe harbour provisions of the Private

Christiana Serugová, Partner, Tax Leader at PwC Tel.:

Any questions relating to this Methodology Note and / or the report should be directed to:

COUNTRY COMPLIANCE UPDATES

Working Group on Bribery: 2012 Data on Enforcement of the Anti-Bribery Convention

EMERGING TRENDS IN LATIN AMERICA

Sadzobník kartových poplatkov firemné platobné karty / Schedule of Card Charges company payment cards

Best Practices for Cross-Border Investigations and Due Diligence. European Compliance & Ethics Institute February 27, 2018

OVERVIEW OF INTERNATIONAL ANTI-BRIBERY LAWS

Pharma Cooperation Code Transparency Report Methodological Note. Pfizer Switzerland

OTSUKA PHARMACEUTICAL EUROPE LTD ( OTSUKA EUROPE ) EFPIA DISCLOSURE: AUSTRIA METHODOLOGY NOTE APPLICABLE TO TRANSFERS OF VALUE.

Back to the Basics An End of the Year Review of the FCPA

Anti-Bribery & Anti-Corruption Compliance in Russia

Yes Santa Claus, there is Anti-Corruption Enforcement in Canada

The U.S. Foreign Corrupt Practices Act (FCPA):

GLOBAL BUSINESS. a series of stages that include: 1. Exporting. 4. Wholly owned subsidiaries 5. Global sourcing.

The Pharmaceutical Market: Did we Learned the Crisis Lessons? Petru Crăciun ZF Pharma Bucharest 2014, September 29th

International Business Transactions. FCPA, OECD Convention and OECD Member States New Legislation

An Overview of the Foreign Corrupt Practices Act

Toshifumi Ishida. International Safety and Security Cooperation Division Ministry of Foreign Affairs of Japan

Cegedim Q Revenue Highlights th. August 3 th, 2011

DISCLOSURE OF TRANSFERS OF VALUE TO HEALTHCARE PROFESSIONALS AND HEALTHCARE ORGANISATIONS IN THE UK

Avoiding Fraud and Corrupt Practices. Michael Steinberg IES Abroad AIEA Conference February 2014

Policy Debate: Perspectives on Global Device Industry Ethics & Compliance Initiatives

Anti-corruption Authorities Initiative: Survey on the Effectiveness of Anticorruption

BRIBERY IN INTERNATIONAL BUSINESS TRANSACTIONS

Myanmar. Lex Mundi Global Anti-Corruption Compliance Guide. Submitted by Tilleke & Gibbins, the Lex Mundi member firm for Thailand / 27 Nov 2018

NEW DUTIES OF FRENCH AN D HONG KONG COMPANIES IN LINE WITH OECD S UPSCALED STANDARD TO FIGHT AGAINST MONEY LAUNDERING WORLDWIDE 1 OUTLINE

Voya Financial Anti-Corruption and Anti-Bribery Policy

Asia-Pac Anti-Corruption Update Roundtable. Panel discussion moderated by: Chris Fordham 14 September 2017

The Perils Of Pharma: The Pharmaceutical Industry And The FCPA

Foreign Corrupt Practices Act December 19, 2017

Beyond the FCPA. A Global Change in Anti-Corruption Enforcement. Presented by: Dana Choi John Irving Sonya Strnad. July 19, 2011

The SEC Whistleblower Law and Pharma Manufacturing in the US and Abroad Neil V. Getnick

Janssen disclosure methodology for 2015

Preparing for the new age of global anti-corruption enforcement Presentation to WPACC. October 15, 2013

Mitsubishi Tanabe Pharma Group Methodology. Transfers of Value to Healthcare Professionals (HCP) and Healthcare Organisations (HCO) in Europe

GDS POLICIES AND PROCEDURES FOR COMPLIANCE WITH FOREIGN CORRUPT PRACTICE ACT

EXECUTIVE COMPENSATION GROUP ADVISORY DISCLOSURE DEVELOPMENTS: EXECUTIVE COMPENSATION. Ernest W. Torain, Jr. Vedder Price P.C.

CORPORATE COMPLIANCE PROGRAM AND ENHANCED COMPLIANCE OBLIGATIONS

Transparency & related issues Some industry considerations

Disclosure Methodological Note For Aventis Pharma Ltd trading as Sanofi

Industry Consolidation: Role of Compliance in Mergers, Acquisitions, and Divestitures

REPUBLIC OF KENYA. STATEMENT Kenya Country Statement delivered during UNCAC BY

UNITED STATES OF AMERICA Before the SECURITIES AND EXCHANGE COMMISSION

Integrity. Bribery Act Procedures

The Tenth International Pharmaceutical Compliance Congress Overview of the Anti-Corruption Landscape. Dr. Peter Dieners Warsaw, 10 May 2016

High Risk Markets & FCPA

The First Asia Pacific Pharmaceutical Compliance Congress & Best Practices Forum

2017 Year-End Review: Anti-Corruption Trends and Other Corporate Enforcement Issues

Enforcement of Foreign Bribery under the OECD Anti-Bribery Convention

BRIBE, SWINDLE OR STEAL

Presentation by Economy Under Review - Viet Nam

CARDAX, INC. FOREIGN CORRUPT PRACTICES ACT COMPLIANCE POLICY

GOLD RESOURCE CORPORATION FOREIGN CORRUPT PRACTICES ACT COMPLIANCE POLICY Confirmed December 7, 2018

Safe Harbor Statement

Foreign Corrupt Practices Act Policy

Q PRESENTATION 13 JULY 2018

Anti-corruption and compliance in Russia

Anti-bribery andforeign Corrupt Practices Act Policy

Agenda. EFPIA Disclosure Rules - Basics Latest Developments in Transcription As of 1/15/14

IMPLEMENTATION OF THE SYSTEM OF HEALTH ACCOUNTS: THE GREEK EXPERIENCE. Professor Em. L. Liaropoulos (Project coordinator)

FCPA: Enforcement, Investigations and Compliance

Anti-Bribery Policy. Copyright Oceanscan All rights reserved 2012 Page 1 of 5

U.K. Bribery Act Implications for Companies Doing Business in the United Kingdom. Wednesday, 28 July 2010

G20 Finance Track. 18 Februari 2016

Recent FCPA Enforcement Action

US Antitrust Issues Trends In Cartel Enforcement Niall E. Lynch June 20, 2011

Foreign Corrupt Practices Act Policy August 16, 2017

Compliance. TODAY March Meet Donna Abbondandolo

ANTI-CORRUPTION AND ANTI-BRIBERY POLICY

Foreign Corrupt Practices Act. 15 February 2018

US FCPA and UK Bribery Act

Cegedim: First half is 2011 on target.

Cegedim: EBITDA margin nearly stable in the first half of 2014

Jefferies 2014 Global Healthcare Conference. June 4, 2014

Promoting Medical Products Globally

Establishing an Anti-Corruption Compliance Program in Canada

Key Liabilities facing clubs Overview of Liability cover included in BASC membership DIRECTORS & OFFICERS LIABILITY BASC

Instant download and all chapters Test Bank Global Marketing Management 8th Edition Keegan

Anti-Bribery. Statement of Policy

Statistical annex. The digital economy 2007

University of California, Berkeley

LATAM Anti-Corruption Update. Cory LaBarge Chief Compliance Officer LATAM Grunenthal Group

Mark Bartlett Davis Wright Tremaine LLP

ABP as a force for good

Avoiding Anti-Corruption Missteps in a Global Market. November 30, 2017

Transparency guidelines and disclosure payments in the pharmaceutical industry

Safe Harbor Statement

T.R.A.D.E. Hot Topics Bratislava, October 2017

ANTI-CORRUPTION POLICY

OIL & GAS SUPPLY CHAIN: Compliance Considerations for International Energy Companies

Overview of the U.S. Foreign Corrupt Practices Act

Lessons Learned about Anti- Bribery Foreign Corrupt Practices from Recent Cases

Law Amendment and the FCPA Best Practices for Responding to a Chinese Government Commercial Bribery Investigation

Investment Management Institute 2017

Methodology for Compliance with the ABPI Disclosure Code. Introduction Page 1. General Comments Page 2. Indirect Transfers of Value Page 3

Corruption and Compliance Programs: Comparison of French and U.S. Approaches

Transcription:

CEGEDIM produktové protfólio 6.11.2012 Hotel Kaskády

Cegedim predstavenie od roku 1969 43 ročná skúsenosť 8 200 zamestnancov priame zastúpenie v 43 krajinách sveta poskytovaná podpora vo viac ako 80 krajinách Obrat v roku 2010: 927 miliónov Euro Viac ako 600 klientov celosvetovo 1 000 200 000 medicínskych zástupcov používa Cegedim 900,0 CRM 900 37% market share vo farmaceutickom priemysle celosvetovo 800 Cegedim total Sales (million ) 700 600 541,0 500,0 500 427,5 389,0 400 300 200 756,0 840,0 927,0 100 2003 2004 2005 2006 2007 2008 2009 2010 2

Cegedim SK produktové portfólio CRM riešenie (18 klientov) Mobile Intelligence, TEAMS Databáza OneKey (22 klientov) Direct mailing market leader Marketingové prieskumy recall test Compliance riešenie Xtelligence analytický nástroj ďalšie produkty 3

Compliance riešenie 6.11.2012 Hotel Kaskády

Agenda Globálne trendy a ciele Compliance Súčasný stav na Slovensku AggregateSpend360 Záver otázky 6

GLOBÁLNY POHĽAD - NARIADENIA V RÁMCI EU 7

GLOBÁLNE TRENDY 8

Súčasné globálne trendy + EU Druh nariadenia/ smernice Povinnosť spoločnosti Pôsobnosť Sankcie a pokuty State Laws Promotional spend reporting U.S. Financial penalties Federal Law (PPACA 6002) Promotional spend reporting and public disclosure U.S. Financial penalties ABPI (UK Pharma Assoc.) Speaker, consultant, ad board fees reporting UK Self regulation France Law Fall 2011 Spend data reporting and public disclosure France Financial penalties CGR/Nefarma (Dutch Pharma. Association) Spend data reporting and public disclosure The Netherlands Self regulation Slovakia JPMA (Japan Pharma Assoc.) Australia (Medicines Australia Assoc.) Spend data reporting and disclosure Spend data reporting and public disclosure Slovakia Japan Financial penalties Self regulation Spend data reporting Australia Self regulation UK Bribery Act Foreign Corrupt Practices Act (FCPA) Adequate anti-bribery preventive measures Clean Books of records Anti-bribery measures Global Global Financial penalties / civil and criminal prosecution Financial penalties / civil and criminal prosecution 10

Legislativne podmienky SR Povinnosť farmaceutickej spoločnosti alebo distribútora: Od 1.12.2011 Zoznam účastníkov lekárskych podujatí Meno Priezvisko Domáca adresa Národné centrum zdravotníckych informácií (NCHI) 13

Legislatívne podmienky SR Povinnosť lekára resp. zdravotníckeho poskytovateľa: Od 1.12.2011 Informovať Ministerstvo zdravotníctva 1. Peňažný alebo nepeňažný príjem 2. Názov plátcu 3. Meno príjemcu 4. Adresa zdravotníckeho zariadenia 5. Účel pre prijatie odmeny Ministerstvo zdravotníctva (MOH) 14

Legislativne podmienky SR Povinnosť farmaceutickej spoločnosti, distribútora liečiv...: Od 1.12.2011 Informovať Ministerstvo zdravotníctva Marketingové náklady Marketingové a nepeňažné benefity poskytnuté (HCP) na pravidelnej báze Ministerstvo zdravotníctva (MOH) 15

AggregateSpend360 Architecture Interná apl. ERP (SAP) T&E Automatický prenos Transparentnosť Distribúcia CRM Cestovná agentúra Integrácia, validácia a spend data management Priebežný systém varovania Preddefinované reporty Na mieru reporty Analýza dát Informovanie a odsúhlasenie prijímateľom Spend data rozposlanie Klinické štúdie Vzdelávanie Manuálny zápis alebo load súboru Denne aktualizovaná databáza lekárov, lekární a zdrav.inštitúcií s priebežnou validáciou 19

Ďakujem za pozornosť Email: michal.kapusta@cegedimdendrite.com www.cegedim.com 20